艾昆緯-制藥公司的凍結(jié)資產(chǎn)-冷鏈藥品 Pharmas Frozen Assets Cold chain medicines

hitePaperColdchainmedicinesEFANLUTZMAYERConsultantEMEAThoughtLeadershipIQVIA|3olsdfthealsemsoalsntoaceaelyMedicines50Naturalgasprices2%Containercostshave50Naturalgasprices2%ContainercostshaveincreasedbyContainercostsAPIprecursorspriceshaveAPIprecursorpricesShortagesofrawmaterialsandlabourSupplychainpressuremeegsambienttemperatures.ytontalataFigure1:MacroeconomicfactorsimpactthesupplychainofpharmaceuticalcompaniesProducerPriceIndex1NaturalgaspriceshaveNaturalgaspriceshaveincreasedbyUSAEuroareaJanJanJan|5ApproachtodefiningcoldchainmedicinestosionchannelsegelFigure2:DefinitionandmethodologyofcoldchainmedicinesWorkflowBiologics?TakeallbiologicsfromIQVIAMIDAS?CategorisebychemicalfamilyNIHDailyMed?UseNIHDailyMeddatabasetoidentifystorageconditions?AssigntemperatureattributeatthemoleculelevelColdChainormarketsegmentationTemperatureRangesDEGREEDEGREECELSIUSHeparinsMonoclonalAntibodiesRNAVxCellTxAmbientRefrigeratedFrozenTEMPERATUREEXAMPLESDailyMedSection16:“Howsupplied/storageandhandling”Source:IQVIAEMEAThoughtLeadership;/dailymed/index.cfmNotes:VaccinesandCOVID-TxareexcludedThecoldchainisthetermgiventoanuninterruptedtemperature-controlledsupplychainthatencapsulatesproduction,storageanddistributiontomaintainqualityandsafetyfrombenchtobedside.ines27%30%$384bn27%30%$384bn20%23%AntidiabeticsOncologyImmunology39%38%SU6bn6%%gyThecoldchainmarket:aglobaloverviewueColdchainmedicinesgrewmorethantwiceasfastat13%comparedto6%forthetotalmarketbetween2017and2022.pyFigure3:GlobalcoldchainmarketexclusiveofvaccinesandCOVID-19therapeuticsGlobalcoldchainpharmamarket(exclusiveofvaccines)VolumeSUsBnVolumeSUsBnValue6868%32%nds|787%%%84%88%77%666693%93%%%87%%%84%88%77%666693%93%%%Figure4:Top20pharmacontributiontocoldchainmedicinesAmbientColdAmbientTop20Pharma(%,USDbillion)AllothersTop2012%3%14%12%3%14%2%88%%45%55%ColdchainAmbientindFigure5:ColdchainmedicinesmarketdevelopmentGlobalcoldchainmarketvalueGlobalGlobalcoldchainmarketvalue2022GrowthratesVolume 6% % %Value % %Source:IQVIAEMEAThoughtLeadership;IQVIAMIDASMATQ32022;Rx-only;OurWorldinData;CompanyFinancialReports.Notes:ExclusiveofvaccinesexceptforCOVID-19.ttmeVACCINES–AHIGH-VOLUMECOLDCHAINMARKETablereBiologicshavebeenakeygrowthdriveroverthelastdecade.Thiswilllikelycontinueasbiologicsrepresent49%oftheglobalpipeline.Lossofexclusivityandmeasurestoincreasebiosimilarusageinhigh-incomecountrieswillincreasetheir|925%Figure6:GlobalATMPmarketdevelopment25%GlobalATMPmarketdevelopment(USDbillion) 28%24%24%%31%20%21%22%75%22%75%54%64%54%48%3%78%3%H12022 41%5%9%ATMPinsightsHighlycomplexproceduredoneinspecialisedhospitalsettingandinvolvehighcostsperpatient.samplesneedultra-lowfreezingand$20bnmarketwith26%CAGRandtementsLOGISTICALCHALLENGESAROUNDNEXT-GENERATIONBIOTHERAPEUTICSenTfsImplicationsforpharmaandlogisticscompaniesofddetherelowareysndstorageofwastheoxaseChallengesaroundvaccinecold-chainlogisticsremainespeciallyacuteandaretwofold:1.Theyarehighvolumeproductsand2.needtoreacheventhemostisolatedandofoftenverypoorpopulations.Inotherwords,low-incomecountrieswithoutsophisticatedcoolinginfrastructure.Incontrast,thecomplexlogisticsofhighvalue/lowvolumeATMPsareachallengeofhigh-incomecountries.iqviacom11Figure7:ConsiderationsforpharmaandlogisticscompaniesLogisticsEnvironmentBiomedicalinnovationSource:IQVIAEMEAThoughtLeadership.Mastercoldchainlogisticcomplexity?Capturethevalueinarapidlygrowingmarketsegment?LimittemperaturefluctuationduringlastmiledeliveryReduceenvironmentalimpact?Useofgreenerfuelsandpassivecoolingwhenpossible?ManufactureclosertopatientsExploreambienttemperaturealternatives?Optimisedrugformulationtoimprovestability?Explorenewdrugdeliverysystemstyofprogrammes.22leateesdssoranesranduresnsConclusionsegment.es